However, in cells exhibiting defective HR, such as breast cancer cells with pathogenic BRCA1/2 mutations, defects cannot be repaired, leading to tumor-specific cell death (Lord and Ashworth, 2017). This evidence concerns the gene BRCA1 and breast carcinoma.